Clinical trials: Crohn Disease of Ileum
Crohn Disease
Small Bowel Deep Learning Algorithm Project
Crohn's disease affects 200,000 people in the UK (~1 in 500), most are young (diagnosed < 35 years) with costs of direct medical care exceeding £500 million.
- Trial name
- NCT03706664
- Testing
- Machine learning algorithm
- Where
- United Kingdom
- Volunteers
- 226 people
- Sponsor
- London North West Healthcare NHS Trust
Crohn Disease, Recurrence
Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.
The objective of this study is to evaluate if in the prevention of postoperative recurrence of ileal Crohn's disease immediate initiation of azathioprine postoperatively is superior to delayed (6- 12 mths.) introduction of…
- Conditions
- Crohn Disease, Recurrence, Azathioprine, Prevention
- Trial name
- NCT02247258
- Testing
- Azathioprine, Azathioprine in case of endoscopic recurrence, Ileocolonoscopy
- Where
- 4 sites in Belgium, Czechia and 1 more
- Volunteers
- 63 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Crohn Disease of Ileum
Ileocolic Resection for Complex Crohn's Disease
Laparoscopic ileocolic resection is the preferred surgical approach for patients with ileocecal Crohn's disease (CD). Objective of this study was to evaluate the efficacy of a minimally invasive gas-less ileocolic resection in…
- Trial name
- NCT03950726
- Testing
- ileocolic resection
- Volunteers
- 27 people
- Sponsor
- University of Roma La Sapienza
Crohn's Disease
Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
The purpose of this study is to evaluate the clinical efficacy of D9421-C 9 mg once daily compared to Mesalazine 1 g three times a day to patients with mild to moderate active Crohn's disease affecting ileum, ileocecal region…
- Trial name
- NCT01514240
- Testing
- D9421-C capsule 3 mg, Mesalazine tablets
- Where
- 25 sites in Japan
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Crohn Disease (CD)
Concordance Between Inflammatory Activity Assessed by Enteric MRI With and Without Intestinal Distension Product in Patients With Ileal Crohn's Disease.
Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that can significantly impair patients' quality of life. Due to its transmural nature (affecting the entire thickness of the intestinal wall), it naturally…
- Trial name
- CONFORT (NCT07471438)
- Testing
- MRI
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Clermont-Ferrand
Crohn Disease (CD), Crohn Disease of Ileum
Laparoscopic Right Hemicolectomy for Crohn's Disease of the Terminal Ileum Utilizing the Mesenteric Excision and Exclusion
This study is designed for patients requiring surgery for Crohn's disease of the terminal ileum. A combination of laparoscopic segmental right colectomy with extended mesenteric excision and the Kono-s anastomosis will be…
- Conditions
- Crohn Disease (CD), Crohn Disease of Ileum, Kono S Anastomosis, Extended Mesenteric Excision
- Trial name
- NCT07231601
- Testing
- Mesenteric excision and exclusion
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tzaneio General Hospital
Crohn's Disease
High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children
The purpose of this 4 week study is to determine whether PASER®, an approved delayed-release oral formulation of 4-aminosalicylic acid, in doses of 50 milligrams per kilogram three times daily for 2 weeks followed by 50…
- Trial name
- NCT00495521
- Testing
- 4-Aminosalicylic acid extended release granules
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Jacobus Pharmaceutical